Fatal cardiotoxicity often the cost of beating pediatric cancer

  • "It appears that for some of these survivors we have substituted one fatal disease of childhood -- cancer -- for another fatal disease of early adult life." -- Steven E. Lipshultz, MD

That almost says it all.

New research published in the Journal of Clinical Oncology indicates that the risk of childhood cancer survivors dying from cardiovascular causes later in life goes up with the dose of radiation received by the patient's heart during treatment. In fact they have a 60% higher risk than the general population.

The research not only looked at cardiovascular mortality from the radiation but also from chemotherapy received.

Added Dr. Lipshultz, "These are the exact concerns we've had based on careful subclinical assessments of how the heart in these survivors has been working."

By Ross Bonander

You can read a more detailed summary of these findings at MedPageToday.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap